Miralles Gines Diego sold $4K of ARTV

Miralles Gines Diego (President & Head of R&D) sold 1,043 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 on 2026-11-17.

Original reporting
SEC EDGAR · Miralles Gines Diego
Published Nov 18, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The filing provides incremental information about insider selling activity but does not include guidance, trial results, financing, or regulatory actions.

02

Market read

Traders may note insider selling, but the disclosed transaction value is small and is unlikely to drive a material repricing by itself.

03

What to watch

Insider sales often reflect routine diversification, tax planning, or personal liquidity, and Form 4 does not reveal intent beyond the transaction details.

Relevance 3/10Novelty 3/10Timing: filed 2026-11-18, transaction dated 2026-11-17

Background

The article is a SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Artiva Biotherapeutics disclosed an insider open-market sale by its President and Head of R&D of 1,043 shares at $3.9119 on 2026-11-17.

Expected impact

Likely limited downside pressure or no sustained move as the transaction size is modest and lacks a stated 10b5-1 plan.

Evidence & confidence

Form 4 insider sales can be interpreted as liquidity or diversification; here the disclosed value is about $4.1k and there is no indication of a broader corporate event.

Market effects

No clear sector read-through from a single small insider sale at a biotech.

None.

None.

Counterpoint

The absence of a 10b5-1 plan could be viewed as more discretionary selling, but the dollar amount is too small to be a strong signal.

Key entities

  • Artiva Biotherapeutics, Inc.

    US-listed biotech subject of the Form 4 insider sale disclosure.

  • Miralles Gines Diego

    President and Head of R&D who sold 1,043 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.